This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

There has been increasing interest in the use of 5% imiquimod cream in the treatment of patients with superficial basal cell carcinomas (sBCCs). To date, the reports of its efficacy apply to single tumors in individuals.^1-3 However, in clinical practice it is common for patients to have more than 1 sBCC when they present for treatment.⁴ The aim of this study was to assess the safety and efficacy of 2 dosing regimens of 5% imiquimod cream for the treatment of patients with multiple sBCCs.

Methods and Results

Sixty-seven adults with a total of 208 histologically confirmed sBCCs on their trunk, limbs, or neck (2-6 tumors per person) applied 5% imiquimod cream 7 times per week or 5 times per week for 6 weeks. Twelve weeks after treatment, the tumor sites were examined clinically and histologically for evidence of residual tumor.

Sixty subjects (90%) had 2 to 4 target tumors. One hundred sixty-one tumors . . . [Full Text of this Article]

Comment
Robin Marks, MBBS; Mary Owens, MD; Shelley-Ann Walters for the Australasian Multi-Centre Trial Group

Correspondence: Dr Marks, Department of Dermatology, University of Melbourne, St Vincent's Hospital, Fitzroy, Victoria 3065, Australia (jossr@svhm.org.au).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients: Randomized, Double-blind, Placebo-Controlled Trial
Brown et al.
Arch Dermatol 2005;141:985-993.
ABSTRACT | FULL TEXT